Compare Ascendis Pharma A/S (ASND) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs H2O America — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while H2O America trades at $61.47 (market cap $2.57B). The key difference: Ascendis Pharma A/S is far larger — about 6.9× H2O America's market cap, and H2O America pays a 2.86% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HTO | |
|---|---|---|
Market Cap | $17.74B | $2.57B |
Sector | Health | Technology |
52-Week High | $277.18 | $62.42 |
52-Week Low | $163.32 | $44.44 |
Enterprise Value | $18.11B | $4.29B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HTO trades at $61.47, showing minimal daily movement (+0.02%) with strong technical bullish signals from moving averages. The company maintains solid fundamentals with 12.87% net income margin and recent Q1 2026 earnings beat. Analyst consensus is strongly bullish with 80% buy ratings and a $61.33 price target, while the company continues its dividend program with a $0.44 H1-26 payment.
HTO presents a stable investment case with consistent profitability and dividend payments, though growth appears moderate. Key risks include execution of the $2.7 billion capex plan and competitive pressures in the utilities sector. The stock's current valuation appears reasonable with P/E of 21.05, suggesting potential for steady returns rather than explosive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
